GleamWall
中文EN

AIBT AIBOTICS THERAPIES, INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1763329 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-3.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-241.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets937.3%
Debt / equity—
Current ratio0.05x
Interest coverage-9.75x

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-201.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2,183$0
Gross profit$2,183$0
SG&A expense$1.85M$1.63M
Operating income-$1.84M-$1.63M
Interest expense$226,902$213,458
Pretax income-$2.22M-$1.85M
Income tax$0$0
Net income-$2.22M-$1.85M
EBITDA-$1.84M-$1.63M
EPS (diluted)——
Balance sheet
Cash & equivalents$255,940$185,097
Inventory$0—
Current assets$270,107$185,097
PP&E, net$0$0
Intangibles—$1.27M
Total assets$874,673$1.46M
Current liabilities$4.79M$4.85M
Total liabilities$4.83M$4.85M
Shareholders' equity-$3.96M-$3.39M
Shares outstanding486.90M39.99M
Cash flow statement
Operating cash flow-$458,240-$259,037
Financing cash flow$529,083$165,000
Depreciation & amortization$0$498
Stock-based compensation—$0

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.